Eupraxia Pharmaceuticals Reports Positive EP-104GI Treatment Data
Eupraxia Pharmaceuticals announced positive 12-week and 36-week tissue health data from its ongoing Phase 1b/2a part of the RESOLVE trial evaluating EP-104GI for the treatment of eosinophilic esophagitis. Key New Findings from the RESOLVE Trial: Tissue Health Outcomes: At 12 weeks after administration, patients who received the highest dose level of EP-104GI, demonstrated the greatest improvement from baseline measured to date, representing near-complete normalization of tissue health; At 36 weeks after administration, patients in the 4mg/site dose groups maintained the tissue health improvements seen at week 12; A dose-response relationship in EoEHSS Grade and Stage was observed across the EP-104GI dose cohorts ranging from 2.5mg/site to 8 mg site
Trade with 70% Backtested Accuracy
Analyst Views on EPRX
About EPRX
About the author
Eupraxia Pharmaceuticals Reports Significant Tissue Health Improvements in EoE Trial
- Significant Efficacy: In the RESOLVE trial, patients receiving the highest dose (8 mg/site) showed nearly complete normalization of esophageal tissue at 12 weeks, indicating the drug's potential in treating eosinophilic esophagitis (EoE).
- Improved Remission Rates: At 12 weeks (n=19), 58% of patients achieved clinical remission, while 79% maintained remission at 24 weeks (n=14), demonstrating the sustained effectiveness of the treatment.
- Good Safety Profile: To date, over 200 patient-months of follow-up have been reported in 31 patients, with no serious adverse events or cases of oral candidiasis, indicating that EP-104GI is well tolerated at all dose levels.
- Long-term Tracking Data: At 52 weeks (n=6), 67% of patients maintained clinical remission, further validating the drug's long-term efficacy and safety, which may lay the groundwork for future market promotion.
Eupraxia Pharmaceuticals Reports Positive 12-Week and 36-Week Data for EP-104GI in EoE Treatment
- Clinical Trial Progress: Eupraxia Pharmaceuticals announced positive 12-week and 36-week tissue health data from the Phase 1b/2a RESOLVE trial for EP-104GI, indicating the drug's potential in treating eosinophilic esophagitis (EoE), particularly with the highest dose group showing the greatest improvement from baseline.
- Sustained Efficacy: Patients in the 4mg/site dose group maintained their 12-week improvements at 36 weeks, suggesting that the drug not only effectively manages symptoms but also addresses the underlying pathology of EoE at the tissue level.
- Future Data Release: The company expects to release top-line data from the Phase 2b part of the RESOLVE trial in Q3 2026, which will provide critical insights for the further development of EP-104GI and could influence future market positioning and investor confidence.
- Market Reaction: EPRX shares traded at $7.17 in pre-market hours on Nasdaq, down 0.55%, reflecting a cautious market response to the new data, which may impact the company's short-term stock performance.
Eupraxia Pharmaceuticals Shares New 52-Week Follow-Up Data from the RESOLVE Trial on Eosinophilic Esophagitis (EoE) Showing Consistent Outcomes with EP-104GI Treatment
Clinical Trial Results: Cohorts 5 and 6 of the RESOLVE trial show that 4 out of 6 patients remain in clinical remission 52 weeks after a single administration of EP-104GI for eosinophilic esophagitis (EoE), with no serious adverse events reported.
Durability and Tolerability: The data indicates a durable clinical symptom response, with 67% of patients in clinical remission at week 36 and significant reductions in dysphagia symptoms measured by the Straumann Dysphagia Index.
Innovative Treatment Approach: EP-104GI, administered via esophageal wall injections, represents a novel treatment strategy for EoE, potentially offering a once-a-year treatment option that aligns with routine patient endoscopies.
Future Developments: Eupraxia Pharmaceuticals plans to disclose additional data from the RESOLVE trial and is currently recruiting for the Phase 2b part of the trial, with top-line data expected in Q3 2026.
Peterson Capital Organizes Canada Growth Conference in Ireland
Canada Growth Conference: The third Canada Growth Conference is taking place in Dublin, hosted by Peterson Capital, featuring seven of Canada's fastest-growing public companies and over fifty industry professionals.
Event Highlights: Attendees will engage in presentations, networking, and a unique 'Bear Pit' session with CEOs, culminating in a vote for the top growth story, with the winner receiving the Canada Growth Cup.
Eupraxia Pharmaceuticals Completes $80.5 Million Public Offering with Full Underwriter Option Exercised
Successful Public Offering: Eupraxia Pharmaceuticals closed a public offering of 14,636,363 common shares at $5.50 each, raising approximately $80.5 million to support the development of its drug EP-104GI and other clinical initiatives.
Use of Proceeds: The funds will primarily be used for advancing the product pipeline, including clinical trials, regulatory submissions, and expanding the company's intellectual property portfolio, with a focus on addressing significant unmet medical needs.
Eupraxia Pharmaceuticals sets share offering at $70 million
Public Offering Details: Eupraxia Pharmaceuticals has priced its public offering of 12.7 million common shares at $5.50 each, aiming for gross proceeds of approximately $70 million.
Use of Proceeds: The net proceeds from the offering will be utilized for advancing the company's product pipeline, including ongoing preclinical studies, clinical trials, regulatory submissions, and manufacturing scale-up activities.
Eupraxia Pharmaceuticals Reports Significant Tissue Health Improvements in EoE Trial
- Significant Efficacy: In the RESOLVE trial, patients receiving the highest dose (8 mg/site) showed nearly complete normalization of esophageal tissue at 12 weeks, indicating the drug's potential in treating eosinophilic esophagitis (EoE).
- Improved Remission Rates: At 12 weeks (n=19), 58% of patients achieved clinical remission, while 79% maintained remission at 24 weeks (n=14), demonstrating the sustained effectiveness of the treatment.
- Good Safety Profile: To date, over 200 patient-months of follow-up have been reported in 31 patients, with no serious adverse events or cases of oral candidiasis, indicating that EP-104GI is well tolerated at all dose levels.
- Long-term Tracking Data: At 52 weeks (n=6), 67% of patients maintained clinical remission, further validating the drug's long-term efficacy and safety, which may lay the groundwork for future market promotion.
Eupraxia Pharmaceuticals Reports Positive 12-Week and 36-Week Data for EP-104GI in EoE Treatment
- Clinical Trial Progress: Eupraxia Pharmaceuticals announced positive 12-week and 36-week tissue health data from the Phase 1b/2a RESOLVE trial for EP-104GI, indicating the drug's potential in treating eosinophilic esophagitis (EoE), particularly with the highest dose group showing the greatest improvement from baseline.
- Sustained Efficacy: Patients in the 4mg/site dose group maintained their 12-week improvements at 36 weeks, suggesting that the drug not only effectively manages symptoms but also addresses the underlying pathology of EoE at the tissue level.
- Future Data Release: The company expects to release top-line data from the Phase 2b part of the RESOLVE trial in Q3 2026, which will provide critical insights for the further development of EP-104GI and could influence future market positioning and investor confidence.
- Market Reaction: EPRX shares traded at $7.17 in pre-market hours on Nasdaq, down 0.55%, reflecting a cautious market response to the new data, which may impact the company's short-term stock performance.
Eupraxia Pharmaceuticals Shares New 52-Week Follow-Up Data from the RESOLVE Trial on Eosinophilic Esophagitis (EoE) Showing Consistent Outcomes with EP-104GI Treatment
Clinical Trial Results: Cohorts 5 and 6 of the RESOLVE trial show that 4 out of 6 patients remain in clinical remission 52 weeks after a single administration of EP-104GI for eosinophilic esophagitis (EoE), with no serious adverse events reported.
Durability and Tolerability: The data indicates a durable clinical symptom response, with 67% of patients in clinical remission at week 36 and significant reductions in dysphagia symptoms measured by the Straumann Dysphagia Index.
Innovative Treatment Approach: EP-104GI, administered via esophageal wall injections, represents a novel treatment strategy for EoE, potentially offering a once-a-year treatment option that aligns with routine patient endoscopies.
Future Developments: Eupraxia Pharmaceuticals plans to disclose additional data from the RESOLVE trial and is currently recruiting for the Phase 2b part of the trial, with top-line data expected in Q3 2026.
Peterson Capital Organizes Canada Growth Conference in Ireland
Canada Growth Conference: The third Canada Growth Conference is taking place in Dublin, hosted by Peterson Capital, featuring seven of Canada's fastest-growing public companies and over fifty industry professionals.
Event Highlights: Attendees will engage in presentations, networking, and a unique 'Bear Pit' session with CEOs, culminating in a vote for the top growth story, with the winner receiving the Canada Growth Cup.
Eupraxia Pharmaceuticals Completes $80.5 Million Public Offering with Full Underwriter Option Exercised
Successful Public Offering: Eupraxia Pharmaceuticals closed a public offering of 14,636,363 common shares at $5.50 each, raising approximately $80.5 million to support the development of its drug EP-104GI and other clinical initiatives.
Use of Proceeds: The funds will primarily be used for advancing the product pipeline, including clinical trials, regulatory submissions, and expanding the company's intellectual property portfolio, with a focus on addressing significant unmet medical needs.
Eupraxia Pharmaceuticals sets share offering at $70 million
Public Offering Details: Eupraxia Pharmaceuticals has priced its public offering of 12.7 million common shares at $5.50 each, aiming for gross proceeds of approximately $70 million.
Use of Proceeds: The net proceeds from the offering will be utilized for advancing the company's product pipeline, including ongoing preclinical studies, clinical trials, regulatory submissions, and manufacturing scale-up activities.
